Overview
- The Weill Family Foundation has committed a $100 million matching gift to the Weill Cancer Hub West, and UCSF and Stanford have already raised about $25 million toward the $200 million goal.
- The hub’s inaugural grants support four ambitious research streams: CRISPR-based in vivo immunotherapy, personalized cell therapies for solid tumors, metabolic/diet-based cancer interventions, and AI-driven personalized treatment planning.
- Nobel laureate Jennifer Doudna is collaborating on the in-body CRISPR project, and teams led by Crystal Mackall and Justin Eyquem aim to secure FDA investigational new drug approval and launch first clinical trials within three years.
- Researchers will probe how GLP-1 agonists like Ozempic and Wegovy influence inflammation and cancer progression to identify metabolic levers that may enhance treatment efficacy.
- By pooling data and expertise across UCSF and Stanford through this collaborative hub, researchers plan to accelerate translational breakthroughs at a time when federal funding has grown less predictable.